US4888339A
Expired / Lapsed
US
⏱️ 0.0 years remaining
Agent for prophylaxis and treatment of cardiac hypertrophy
Assignee: Tanabe Pharma Corp
•
Filing: 1987-12-09
•
Granted: 1989-12-19
•
Expires: 2007-12-09
Abstract
Abstract Novel agent for the propylaxis and treatment of heart failure, which comprises as an active ingredient a 2-oxo-imidazolidine compound of the formula: <CHEM> wherein R<1> and R<2> are the same or different and are each a lower alkyl group, R<3> is a phenyl-substituted lower alkyl group, and R<4> is hydrogen atom or a lower alkyl group, or a pharmaceutically acceptable salt thereof.
Inventors
- 👤 Masami Kubo
- 👤 Takashi Ochiai
- 👤 Hirofumi Yuasa
Bibliographic Details
Application Number
—
Jurisdiction
US
Data Source
google_patents
Last Synchronized
2026-10-31 13:00
CPC Classifications
A; A61; A61K; A61K38/00; A61K38/04
Claims Analysis
Total Claims: 8
Claim 1
Independent Claim
77 words
A method for the prophylaxis and treatment of cardiac hypertrophy in a warm-blooded animal, which comprises administering to said warm-blooded animal a prophylactically or therapeutically effective amount of 2-oxo-imidazolidine compound of the formula: ##STR3## wherein R 1 and R 2 are the same or different and are each a lower alkyl group, R 3 is a phenyl-substituted lower alkyl group, and R 4 is hydrogen atom or a lower alkyl group, or a pharmaceutically acceptable salt thereof.
Claim 2
Independent Claim
77 words
A method for the prophylaxis and treatment of cardiac hypertrophy in a warm-blooded animal, which comprises administering to said warm-blooded animal a prophylactically or therapeutically effective amount of 2-oxo-imidazolidine compound of the formula: ##STR3## wherein R 1 and R 2 are the same or different and are each a lower alkyl group, R 3 is a phenyl-substituted lower alkyl group, and R 4 is hydrogen atom or a lower alkyl group, or a pharmaceutically acceptable salt thereof.
Claim 3
Dependent Claim
82 words
The method according to claim 1, wherein the compound to be administered is a compound of formula (I) wherein R 1 is an alkyl group having 1 to 4 carbon atoms, R 2 is an alkyl group having 1 to 4 carbon atoms, R 3 is a phenyl-substituted alkyl group having 1 to 4 carbon atoms in the alkyl moiety, and R 4 is hydrogen atom, or an alkyl group having 1 to 4 carbon atoms or a pharmaceutically acceptable salt thereof.
Claim 4
Dependent Claim
45 words
The method according to claim 1, wherein the compound to be administered is a compound of the formula (I) wherein R 1 is methyl, R 2 is methyl, R 3 is phenethyl, and R4 is hydrogen atom or ethyl or a pharmaceutically acceptable salt thereof.
Claim 5
Dependent Claim
53 words
The method according to claim 1, wherein the compound to be administered is a compound of the formula (I) wherein the carbon atoms at 4-position of the oxoimidazolidine ring and at 2-position of the amino acid moiety of the formula: --NH--CH(R 3 )COOR 4 are both S-configuration or a pharmaceutically acceptable salt thereof.
Claim 6
Dependent Claim
65 words
The method according to claim 1, wherein the compound to be administered is a compound of the formula (I) wherein the carbon atoms at 4-position of the oxoimidazolidine ring, at 2-position of the alkanoyl moiety of the formula: --COCH(R 2 )-- and at 2-position of the amino acid moiety of the formula: --NH--CH(R 3 )COOR 4 are all S-configuration or a pharmaceutically acceptable salt thereof.
Claim 7
Dependent Claim
21 words
The method according to claim 1, wherein the compound to be administered is (4S)-1-methyl-3-[(2S)-2-[N-((1S)-1-ethoxycarbonyl-3-phenylpropyl)amino]propionyl]-2-oxo-imidazolidine-4-carboxylic acid or a pharmaceutically acceptable salt thereof.
Claim 8
Dependent Claim
21 words
The method according to claim 1, wherein the compound to be administered is (4S)-1-methyl-3-[(2S)-2-[N-((1S)-1-carboxy-3-phenylpropyl)amino]propionyl]-2-oxo-imidazolidine-4-carboxylic acid or a pharmaceutically acceptable salt thereof.
References Cited (Backward Citations)
US4416895A
Cited
US4587258A
Cited
EP0078545A1
Cited
EP0095163A2
Cited
US4508727A
Cited
JPS61158968A
Cited
JPH0613715A
Cited
USPTO Annuity & Maintenance Windows
| Annuity Stage | Window Opens | Payment Deadline | Surcharge Period Until | Estimated Fee | Status |
|---|---|---|---|---|---|
| 3.5 Years (Year 4) | 1992-12-18 | 1993-06-19 | 1993-12-19 | $2000.00 | Window Closed / Lapsed |
| 7.5 Years (Year 8) | 1996-12-18 | 1997-06-19 | 1997-12-19 | $3760.00 | Window Closed / Lapsed |
| 11.5 Years (Year 12) | 2000-12-18 | 2001-06-19 | 2001-12-19 | $7700.00 | Window Closed / Lapsed |